363 related articles for article (PubMed ID: 23421968)
1. Effect of fluticasone/salmeterol combination on dyspnea and respiratory mechanics in mild-to-moderate COPD.
Guenette JA; Webb KA; O'Donnell DE
Respir Med; 2013 May; 107(5):708-16. PubMed ID: 23421968
[TBL] [Abstract][Full Text] [Related]
2. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
O'Donnell DE; Sciurba F; Celli B; Mahler DA; Webb KA; Kalberg CJ; Knobil K
Chest; 2006 Sep; 130(3):647-56. PubMed ID: 16963658
[TBL] [Abstract][Full Text] [Related]
3. Effect of adjunct fluticasone propionate on airway physiology during rest and exercise in COPD.
Guenette JA; Raghavan N; Harris-McAllister V; Preston ME; Webb KA; O'Donnell DE
Respir Med; 2011 Dec; 105(12):1836-45. PubMed ID: 21917440
[TBL] [Abstract][Full Text] [Related]
4. Sensory-mechanical relationships during high-intensity, constant-work-rate exercise in COPD.
O'Donnell DE; Hamilton AL; Webb KA
J Appl Physiol (1985); 2006 Oct; 101(4):1025-35. PubMed ID: 16675610
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD.
Jensen D; Amjadi K; Harris-McAllister V; Webb KA; O'Donnell DE
Thorax; 2008 Jul; 63(7):606-13. PubMed ID: 18250181
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD.
O'Donnell DE; Laveneziana P; Ora J; Webb KA; Lam YM; Ofir D
Thorax; 2009 Mar; 64(3):216-23. PubMed ID: 19052054
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.
Mahler DA; Wire P; Horstman D; Chang CN; Yates J; Fischer T; Shah T
Am J Respir Crit Care Med; 2002 Oct; 166(8):1084-91. PubMed ID: 12379552
[TBL] [Abstract][Full Text] [Related]
8. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.
Cazzola M; Andò F; Santus P; Ruggeri P; Di Marco F; Sanduzzi A; D'Amato M
Pulm Pharmacol Ther; 2007; 20(5):556-61. PubMed ID: 16914336
[TBL] [Abstract][Full Text] [Related]
9. Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease.
Jensen D; Alsuhail A; Viola R; Dudgeon DJ; Webb KA; O'Donnell DE
J Pain Symptom Manage; 2012 Apr; 43(4):706-19. PubMed ID: 22168961
[TBL] [Abstract][Full Text] [Related]
10. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
Hanania NA; Crater GD; Morris AN; Emmett AH; O'Dell DM; Niewoehner DE
Respir Med; 2012 Jan; 106(1):91-101. PubMed ID: 22040533
[TBL] [Abstract][Full Text] [Related]
11. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
Jung KS; Park HY; Park SY; Kim SK; Kim YK; Shim JJ; Moon HS; Lee KH; Yoo JH; Lee SD; ;
Respir Med; 2012 Mar; 106(3):382-9. PubMed ID: 21975275
[TBL] [Abstract][Full Text] [Related]
12. Effect of obesity on respiratory mechanics during rest and exercise in COPD.
Ora J; Laveneziana P; Wadell K; Preston M; Webb KA; O'Donnell DE
J Appl Physiol (1985); 2011 Jul; 111(1):10-9. PubMed ID: 21350021
[TBL] [Abstract][Full Text] [Related]
13. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
[TBL] [Abstract][Full Text] [Related]
14. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P;
Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
[TBL] [Abstract][Full Text] [Related]
15. Physiological effects of roflumilast at rest and during exercise in COPD.
O'Donnell DE; Bredenbröker D; Brose M; Webb KA
Eur Respir J; 2012 May; 39(5):1104-12. PubMed ID: 21965226
[TBL] [Abstract][Full Text] [Related]
16. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
17. Effects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD.
Ramlal SK; Visser FJ; Hop WC; Dekhuijzen PN; Heijdra YF
Pulm Pharmacol Ther; 2014 Aug; 28(2):158-64. PubMed ID: 24076367
[TBL] [Abstract][Full Text] [Related]
18. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
Lindberg A; Szalai Z; Pullerits T; Radeczky E
Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
[TBL] [Abstract][Full Text] [Related]
19. Improved respiratory system conductance following bronchodilator predicts reduced exertional dyspnoea.
Diba C; King GG; Berend N; Salome CM
Respir Med; 2011 Sep; 105(9):1345-51. PubMed ID: 21482091
[TBL] [Abstract][Full Text] [Related]
20. Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD.
Dransfield MT; Cockcroft JR; Townsend RR; Coxson HO; Sharma SS; Rubin DB; Emmett AH; Cicale MJ; Crater GD; Martinez FJ
Respir Med; 2011 Sep; 105(9):1322-30. PubMed ID: 21696934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
